Skip to main content

Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS

Objective

Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medicine therapies to the clinic. The objective of ARREST BLINDNESS is therefore to develop and validate new regenerative-based therapies addressing a spectrum of blinding disorders of the cornea. These conditions either have no effective current treatments, depend on a scarce supply of donor tissue, or non-standardized methods are hindering validation of promising regenerative treatments. To achieve our objective, we will implant GMP-fabricated collagen-based bioengineered scaffolds to replace or regenerate the corneal stroma in cases of stromal thinning, scarring, dystrophy or trauma; deliver therapeutic epithelial stem and endothelial cells to the cornea to restore its transparency; deliver regenerative factors to promote neural growth and function; and actively maintain corneal immune privilege in high-risk situations by targeted therapeutic approaches to regress blood and lymphatic vessels. We will additionally develop advanced methods to image and monitor therapy throughout the cycle from GMP-compliant cell and scaffold preparation through the pre- and intra-operative stages, to postoperative follow-up and evaluation. After proof-of-concept and preclinical validation of key enabling components, these technologies will be used by one or several partners in preclinical models and in phase I/II human clinical studies. ARREST BLINDNESS directly addresses the translation of regenerative medicine, bio-artificial organs, tissue engineered scaffolds, and advanced cell and gene therapies into clinical use and will help to alleviate the worldwide problem of corneal blindness.

Field of science

  • /medical and health sciences/medical biotechnology/genetic engineering/gene therapy
  • /medical and health sciences/clinical medicine/ophthalmology
  • /social sciences/economics and business/economics/production economics/productivity

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

LINKOPINGS UNIVERSITET
Address
Campus Valla
581 83 Linkoping
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 623 175

Participants (12)

AEON ASTRON EUROPE B.V.
Netherlands
EU contribution
€ 277 075
Address
J.h. Oortweg 19
2333 CH Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NETHERLANDS INSTITUTE FOR INNOVATIVE OCULAR SURGERY
Netherlands
EU contribution
€ 622 582,50
Address
Laan Op Zuid 88
3071AA Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
EU contribution
€ 738 065
Address
Wilrijkstraat 10
2650 Edegem
Activity type
Research Organisations
KLINIKUM DER UNIVERSITAET ZU KOELN
Germany
EU contribution
€ 1 122 407,50
Address
Kerpener Strasse 62
50937 Koeln
Activity type
Higher or Secondary Education Establishments
UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE
Spain
EU contribution
€ 397 656,25
Address
Avenida De La Universidad S-n
03202 Elche
Activity type
Higher or Secondary Education Establishments
AARHUS UNIVERSITET
Denmark
EU contribution
€ 237 165
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG
Austria
EU contribution
€ 142 800
Address
Nussdorfer Strasse 64/6
1090 Wien
Activity type
Research Organisations
LINKOCARE LIFE SCIENCES AB
Sweden
EU contribution
€ 321 278,75
Address
Mjardevi Science Park, Teknikringen 10, Plan 3
58330 Linkoping
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OPTOMEDICAL TECHNOLOGIES GMBH
Germany
EU contribution
€ 281 222,50
Address
Maria Goeppert Strasse 9
23562 Lubeck
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NOVALIQ GMBH
Germany
EU contribution
€ 149 250
Address
Im Neuenheimer Feld 515
69120 Heidelberg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GENE SIGNAL INTERNATIONAL SA

Participation ended

Switzerland
EU contribution
€ 0
Address
Parc Scientifique Epfl - Pse A
1015 Lausanne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 80 500
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments